Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05676749
Other study ID # CCI-2005
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date February 29, 2024
Est. completion date August 2027

Study information

Verified date February 2024
Source AbelZeta, Inc.
Contact Christine Cornwell
Phone 240-552-5870
Email christine.cornwell@abelzeta.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this Phase 1 clinical study is test tumor infiltrating lymphocytes (known as C-TIL051) with NKTR-255 and anti-PD1 therapy for subjects with refractory non-small cell lung cancer. The purpose of this study is to: 1. Test the safety and ability for subjects to tolerate the TIL therapy 2. Measure to see how the NSCLC responds to the TIL therapy Participants will be asked to: - Provide a tumor sample prior to the start of any treatment which will be used to make the C-TIL051. - Receive standard of care treatment until their lung cancer no longer responds - When necessary, the C-TIL051 will be manufactured by the sponsor and sent back to the site - Subject will then receive chemotherapy (called lymphodepletion) for 3 days followed by 2 days of rest - C-TIL051 will then be infused on day 0 followed by NKTR-255 (IL-15) about 12 to 24 hours later - Pembrolizumab will be administered every 3 weeks for up to 2 years NKTR-255 is a novel polymer-conjugated human IL-15 receptor agonist molecule designed to increase the proliferation and survival of memory CD8+ T cells and enhance the formation of long-term immunological memory which may lead to sustained anti-cancer immune response. The combination of NKTR 255 and TIL's could improve proliferation and persistence of cellular therapies leading to enhanced anti-tumor activity.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date August 2027
Est. primary completion date March 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Able to understand and give written informed consent - Histologically and cytologically confirmed diagnosis of stage IV or recurrent non-small cell lung cancer (NSCLC) with adenocarcinoma or squamous histology - Planned for treatment with an anti-PD1 agent - Tumor accessible by surgery, previously not irradiated and = 1.5 cm in diameter - Measurable disease after resection of tumor by RECIST 1.1 - ECOG = 1 - Expected survival > 6 months - Adequate organ and marrow function - ECHO, MUGA or cardiac stress test within past 6 months showing LVEF >50% and without evidence of reversible ischemia - Pulmonary function tests within past 6 months showing DLCO >50% of predicted Exclusion Criteria: - Previous treatment with PD1/PDL1 inhibitor for metastatic disease, Immune checkpoint blockade (ICB) given as part of definitive therapy for stage Ib-III disease with surgery or after chemo/radiation is acceptable if last dose of ICB is at least 6 months prior to enrollment in this study. - Known driver mutations such as EGFR, ALK, ROS1, RET, METex14, and NTRK alterations. - Current or prior use of any immunosuppressive medications within 14 days before tumor harvest - Known active CNS metastases which are symptomatic - History of leptomeningeal metastases - Uncontrolled intercurrent illness - Known history of HIV+ or AIDS, hepatitis C, acute or chronic active hepatitis B or other serious chronic infection - Live vaccine within 30 days of tumor harvest - History of allogeneic organ transplant - History of primary immunodeficiency - Hypersensitivity to anti-PD1 agent, cyclophosphamide, fludarabine, interleukin-2, gentamicin, or any excipient - Any condition that may interfere with evaluation of study treatment, safety or study results - Active infection that requires IV antibiotics within 7 days of tumor harvest - Unresolved greater than grade 1 toxicity (CTCAE v5.0) from previous therapy - History of interstitial pneumonitis of autoimmune etiology that is symptomatic or requires treatment - Pulmonary disease history requiring escalating amounts of oxygen > 2L - Known autoimmune conditions requiring systemic immune suppression therapy other than low dose prednisone or equivalent. - Other malignancy, other than cutaneous localized) that required active treatment in the last 2 years. - Women who are pregnant or lactating - Women of childbearing potential or fertile men who are unwilling to use effective contraception during study and 6 months after treatment

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
C-TIL051
C-TIL051 given in combination with IL-15 (NKTR-255) and pembrolizumab

Locations

Country Name City State
United States Duke Cancer Institute Raleigh North Carolina

Sponsors (2)

Lead Sponsor Collaborator
AbelZeta, Inc. Nektar Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Collect Blood Samples to Measure the T-cells Before and After C-TIL051 Therapy Collect blood samples to review information about the t-cells present prior to lymphodepleting chemotherapy and after C-TIL051 therapy. up to 24 months
Other Collect Blood Samples to Measure Cytokines prior to and after C-TIL051 Therapy. Collect blood samples and analyze for presence of cytokines at specified intervals before and after treatment with C-TIL051. up to 24 months
Other Collect Blood and Tumor Samples to Measure Circulating DNA Collect blood and tumor samples and analyze for circulating DNA. up to 24 months
Other Collect Blood Samples to Measure Blood RNA Collect blood samples and analyze for RNA sequencing up to 24 months
Other Perform Radiographic Imaging to Review Antitumor Activity Following Treatment Measure by radiographical imaging (CT/MRI scan) and assess response by immune-related response criteria (irRC). up to 24 months
Other Collect and Analyze Tumor Samples for MicroOrganoSphereTM (MOS) Technology Collect tumor sample and review outcome measures by MicroOrganoSphereTM (MOS) Technology. up to 36 months
Primary Calculate the Incidence of Adverse Events or Dose Limiting Toxicities Record the incidence and severity of all adverse events or dose limiting toxicities that occur according to CTCAE criteria V5.0 up to 24 months
Secondary Calculate Objective Response Rate (ORR) of all Subjects Measure by radiographical imaging (CT/MRI scan) the objective response rate using RECIST 1.1 up to 36 months
Secondary Calculate Duration of Response (DOR) of All Subjects Measure by radiographical imaging (CT/MRI scan) the length of response in time. up to 36 months
Secondary Calculate Progression Free Survival (PFS) for All Subjects Measure by radiographical imaging (CT/MRI scan) the length of time to progression of disease. up to 36 months
Secondary Determine Overall Survival (OS) of All Subjects Measure by physical exam and contact reports the overall survival for all subjects following C-TIL051 treatment. up to 36 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04965090 - A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) Phase 2
Recruiting NCT06060613 - Safety and Efficacy of OBX-115 in Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04884282 - Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) Phase 2
Recruiting NCT05236608 - A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC Phase 1/Phase 2
Recruiting NCT04614103 - Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer Phase 2
Recruiting NCT05215340 - Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations Phase 3
Withdrawn NCT06068153 - AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC Phase 2
Not yet recruiting NCT06066138 - A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing Phase 1
Recruiting NCT05429320 - A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) Phase 2
Recruiting NCT05478538 - Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
Completed NCT01773109 - Etirinotecan Pegol (NKTR-102) in NSCLC Phase 2
Recruiting NCT04743505 - Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Recruiting NCT05111197 - Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy Phase 3
Recruiting NCT05555732 - Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) Phase 3
Not yet recruiting NCT05566223 - CISH Inactivated TILs in the Treatment of NSCLC Phase 1/Phase 2
Terminated NCT01060514 - Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer Phase 1
Completed NCT05167500 - Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment
Recruiting NCT05259319 - Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) Phase 1
Enrolling by invitation NCT04697446 - External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
Completed NCT04511533 - Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations Phase 4